Riccardi G, Rivellese AA
Prior analyses have either used models that exclude the results of cardiovascular outcomes trials (with any reductions in cardiovascular and kidney outcomes being extrapolated only from changes in HbA 1c [13]), considered only specific high-risk populations [45, 46], or modelled the populations used in cardiovascular outcomes trials, which represent only 2060% of all people with type 2 diabetes [14]
Mariusz Sikora, Medical University of Warsaw, Poland Updates Copyright 2020 Chen, Li, Zhu, Kuang, Liu, Zhang, Chen and Peng
Consequences of the GSH regulatory motif
International Journal of Molecular Sciences, 21 (13), 4744
Molecular Cell , 80 (3), 384395